Evidence map›Paper›PMID 36873289›Full record

ArticleAfrican journal of laboratory medicine2023

Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda.

Denis Omali, Allan Buzibye, Richard Kwizera, Pauline Byakika-Kibwika, Rhoda Namakula, Joshua Matovu, Olive Mbabazi, Emmanuel Mande, Christine Sekaggya-Wiltshire, Damalie Nakanjako and 10 more

Open access · diamondAbstract read
In one paragraph

Article in African journal of laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 5 countries.

Denis OmaliInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0001-6557-8928
Allan BuzibyeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0001-5874-3219
Richard KwizeraInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0002-5270-3539
Pauline Byakika-KibwikaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0003-0757-1968
Rhoda NamakulaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0002-0013-9083
Joshua MatovuInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0002-1353-5384
Olive MbabaziInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0002-4755-5906
Emmanuel MandeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0003-0587-8181
Christine Sekaggya-WiltshireInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0001-9247-2950
Damalie NakanjakoInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0002-0935-2112
Ursula GutteckDepartment of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-2166-8483
Keith McAdamDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0001-9300-0760
Philippa EasterbrookDepartment of Human Immunodeficiency Virus, World Health Organization, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-2603-5418
Andrew KambuguInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0002-3075-0211
Jan FehrDepartment of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-1113-9895
Barbara CastelnuovoInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0001-7756-5032
Yukari C ManabeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0001-8619-5598
Mohammed LamordeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0003-2218-6822
Daniel MuellerDepartment of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-0856-1879
Concepta MerryDepartment of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0002-2974-5642
Infectious Diseases Institute · UGUniversity of Zurich · CHJohns Hopkins University · USLondon School of Hygiene & Tropical Medicine · GBTrinity College Dublin · IEWorld Health Organization · CH

Funding

HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
FIC NIH HHS D43 TW009771World Health Organization 001
6 · The paper itself

Abstract

Background: Research and clinical use of clinical pharmacology laboratories are limited in low- and middle-income countries. We describe our experience in building and sustaining laboratory capacity for clinical pharmacology at the Infectious Diseases Institute, Kampala, Uganda. Intervention: Existing laboratory infrastructure was repurposed, and new equipment was acquired. Laboratory personnel were hired and trained to optimise, validate, and develop in-house methods for testing antiretroviral, anti-tuberculosis and other drugs, including 10 high-performance liquid chromatography methods and four mass spectrometry methods. We reviewed all research collaborations and projects for which samples were assayed in the laboratory from January 2006 to November 2020. We assessed laboratory staff mentorship from collaborative relationships and the contribution of research projects towards human resource development, assay development, and equipment and maintenance costs. We further assessed the quality of testing and use of the laboratory for research and clinical care. Lessons learnt: Fourteen years post inception, the clinical pharmacology laboratory had contributed significantly to the overall research output at the institute by supporting 26 pharmacokinetic studies. The laboratory has actively participated in an international external quality assurance programme for the last four years. For clinical care, a therapeutic drug monitoring service is accessible to patients living with HIV at the Adult Infectious Diseases clinic in Kampala, Uganda. Recommendations: Driven primarily by research projects, clinical pharmacology laboratory capacity was successfully established in Uganda, resulting in sustained research output and clinical support. Strategies implemented in building capacity for this laboratory may guide similar processes in other low- and middle-income countries.

Indexed as

building laboratory capacityHIVresource-limited settingtherapeutic drug monitoringUganda

Identifiers

PMID36873289
PMCPMC9982508
OpenAlexW4320489961

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.